课题基金 / 基金详情

Clinical significance of comprehensive expression analysis of cancer-related protein in non-small cell lung cancer using tissue microarray technology

Clinical significance of comprehensive expression analysis of cancer-related protein in non-small cell lung cancer using tissue microarray technology
应用组织芯片技术综合分析非小细胞肺癌肿瘤相关蛋白表达的临床意义
批准号:
14571294
负责人:
MITSUDOMI Tetsuya
金额:
$2.24万
依托单位国家:
日本
项目类别:
Grant-in-Aid for Scientific Research (C)
财政年份:
2002
资助国家:
日本
项目状态:
已结题
起止时间:
2002 至 2003

项目摘要

项目成果

MITSUDOMI Tetsuya的其他基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
First, we made TMA containing 976 cases of lung cancers and confirmed its validity by comparing the results obtained by the TMA with those by regular slides or mRNA expression experiments.Using TMA from 241 lung cancer patients, we analyzed expression of p53, p27, RB, EGFR, Bcl2, Synaptophysin, CD56 and TTF1 for their potential prognostic implication. However, only TTF1 showed a marginal prognostic impact among these markers.Thyroid transcription factor (TTF) 1 was expressed throughout the developmental stage of peripheral lung as well as 72% of pulmonary adenocarcinoma, suggesting that TTF1 could serve as a lineage marker of the peripheral lung. In contrast, expression of maspin, which is thought to be involved in motility or invasion of cancer cells, is inversely correlated with TTF1 expression, suggesting that this molecule is related to development of central airway.14-3-3sigma expression was examined in a spectrum of neuroendocrine lung tumors. Most of the tumors belonging to all the four categories of neuroendocrine lung tumors (i.e., carcinoid, atypical carcinoid, neuroendocrine large cell carcinoma, small cell carcinoma) lost expression of 14-3-3sigma in neuroendocrine differentiation.In summary, TMA allowed us rapid evaluation of expression of a given protein in many samples in the same experimental condition, which was very useful for analysis of molecular pathogenesis of lung cancer.
期刊论文(169)
专著(0)
科研奖励(0)
会议论文
光冨徹哉: "分子呼吸器病 ARCHIVES 肺がん"分子呼吸病. 6. 61-65 (2002)
Tetsuya Mitsutomi:“分子呼吸疾病档案肺癌”分子呼吸疾病。 6. 61-65 (2002)
DOI: --
发表时间:
期刊:
影响因子: --
作者: []
通讯作者:
光冨徹哉: "肺癌の予後因子 分子マーカーを中心に"呼吸器科. 2. 201-207 (2002)
Tetsuya Mitsutomi:“肺癌的预后因素,重点关注分子标记”呼吸内科 2. 201-207 (2002)。
DOI: --
发表时间:
期刊:
影响因子: --
作者: []
通讯作者:
光冨徹哉: "遺伝子診断・予後因子"癌の臨床. 49. 1061-1070 (2003)
Tetsuya Mitsutomi:“遗传诊断和预后因素”临床癌症。49。1061-1070(2003)
DOI: --
发表时间:
期刊:
影响因子: --
作者: []
通讯作者:
Koshikawa, K.: "Significant up-regulation of a novel gene, CLCP1, in a highly metastatic lung cancer subline as well as in lung cancers in vivo"Oncogene. 21. 2822-2828 (2002)
Koshikawa, K.:“一种新基因 CLCP1 在高度转移性肺癌亚系以及体内肺癌中显着上调”癌基因。
DOI: --
发表时间:
期刊:
影响因子: --
作者: []
通讯作者:
63
    Molecular targeted therapy against adenocarcinoma of the lung harboring MET exon 14 skipping mutation
    • 批准号:
      16H05433
    • 项目类别:
      Grant-in-Aid for Scientific Research (B)
    • 资助金额:
      $11.23万
    • 财政年份:
      2016
    • 负责人:
      MITSUDOMI Tetsuya
    • 依托单位:
    Molecular analysis of lung adenocarcinomas that do not have mutations in the EGFR pathway and development of therapeutic strategies against them
    • 批准号:
      20390376
    • 项目类别:
      Grant-in-Aid for Scientific Research (B)
    • 资助金额:
      $12.23万
    • 财政年份:
      2008
    • 负责人:
      MITSUDOMI Tetsuya
    • 依托单位:
    Analyses of EGFR and related molecules for individulaization of geftinib treatment for lung cancer
    • 批准号:
      18390386
    • 项目类别:
      Grant-in-Aid for Scientific Research (B)
    • 资助金额:
      $10.18万
    • 财政年份:
      2006
    • 负责人:
      MITSUDOMI Tetsuya
    • 依托单位:
    Molecular and Clinical database and Molecular Staging for Lung Cancer
    • 批准号:
      16591424
    • 项目类别:
      Grant-in-Aid for Scientific Research (C)
    • 资助金额:
      $2.3万
    • 财政年份:
      2004
    • 负责人:
      MITSUDOMI Tetsuya
    • 依托单位: